# Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children

Study · id `cardio:ct-nct04654507` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04654507](<https://clinicaltrials.gov/study/NCT04654507>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04654507

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04654507. Randomized; quadruple masking; primary purpose prevention. Start 2021-03-03 (actual); primary completion 2023-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04654507, source copy `cardio:ctgov-nct04654507-2023-07-25`, retrieved 2026-10-26)
- Started: 2021-03-03 (actual) (ClinicalTrials.gov record NCT04654507, source copy `cardio:ctgov-nct04654507-2023-07-25`, retrieved 2026-10-26)
- Primary completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT04654507, source copy `cardio:ctgov-nct04654507-2023-07-25`, retrieved 2026-10-26)
- Completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT04654507, source copy `cardio:ctgov-nct04654507-2023-07-25`, retrieved 2026-10-26)
- Countries: Qatar (ClinicalTrials.gov record NCT04654507, source copy `cardio:ctgov-nct04654507-2023-07-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04654507-2023-07-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
- Condition: Urinary Tract Infections in Children
- Condition: Dexamethasone
- Condition: Kidney Scarring
- Condition: Acute Pyelonephritis
- Condition: Hypertension in Children
- Condition: Chronic Renal Failure
- Condition: UTI
- Intervention (Drug): Dexamethasone Oral
- Intervention (Drug): Placebo
- Lead sponsor: Hamad Medical Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Hamad Medical Corporation (`cardio:org-hamad-medical-corporation`)

## Provenance

Content hash: 004573ea476b9f945b7790b9ca829a9418b35dbcd749a8821a7385aa0a2e3091
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
